A groundbreaking clinical trial is underway, testing a promising new stem cell treatment for Unilateral Limbal Stem Cell Deficiency (LSCD), a debilitating corneal disease. LSCD occurs when there is a shortage of limbal stem cells, which typically regenerate the cornea as needed. Researchers have identified that this deficiency can lead to significant vision loss, with over 10 million individuals worldwide suffering from corneal blindness due to disease or injury.
The trial focuses on the CALEC procedure, a novel stem cell therapy designed specifically for LSCD. This innovative approach has demonstrated safety and feasibility while showing marked improvements in the surface of the cornea.
“The limbal stem cells are cells that we are born with and then do not produce any additional during our lifetime, so if there’s damage to those, it’s somewhat irreversible,” – Benjamin Bert, MD
Dr. Benjamin Bert highlights the irreversible nature of limbal stem cell damage, making advancements like the CALEC procedure particularly vital. The treatment involves transporting stem cells to a Good Manufacturing Practices (GMP) facility at Dana-Farber Cancer Institute, where they are expanded on a scaffold over two to three weeks.
“So the ability to repopulate those damaged cells using our own cells is a really exciting idea.” – Benjamin Bert, MD
The CALEC procedure offers a significant advantage by using the patient's own cells, potentially circumventing complications associated with traditional transplants from cadaver donors. These older methods required systemic immunosuppression, akin to kidney or lung transplants, which bear significant side effects. Dr. Bert notes that repopulating damaged cells with the patient’s own cells avoids these issues.
“Current treatment options for limbal stem cell deficiency caused by cornea injuries have considerable limitations, including injury to the healthy eye from removal of stem cells, or limited effectiveness.” – Lucia V. Jurkunas
Lucia V. Jurkunas emphasizes the limitations of existing treatments for LSCD. The new procedure minimizes risks to the healthy eye and enhances treatment efficacy. The study's results are promising, with 50% of treated participants experiencing complete cornea restoration within three months.
“The resulting stem cell graft is then brought back to Mass Eye and Ear, where it is transplanted into the patient’s damaged eye,” – Lucia V. Jurkunas
Once expanded, the stem cell graft is returned to Mass Eye and Ear for transplantation into the patient's damaged eye. The CALEC procedure's high safety profile is underscored by the occurrence of only one infection, unrelated to the transplant itself.
“The description of how they’re able to culture these cells requires pretty advanced technology, so it’s a question of can this be expanded so that it can be offered to many patients, or is it going to be limited just to these more academic centers where they have the laboratories and the capabilities to do it,” – Benjamin Bert, MD
While the CALEC procedure shows promise, Dr. Bert raises concerns about its accessibility due to the advanced technology required for cell culturing. The question remains whether this treatment can be scaled beyond specialized academic centers.
Leave a Reply